Persistence of Immune Response to an Adjuvanted Varicella‐Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults
نویسندگان
چکیده
1343. Persistence of Immune Response to an Adjuvanted Varicella‐Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults Karlis Pauksens, MD; Stephanie Volpe, MPH; Tino F. Schwarz, MD; Jan Smetana, MD PhD; Nicole Toursarkissian, MD; Lars Rombo, MD; Stéphanie Ravault, PhD; Marie-Pierre David, MSc; Adriana Bastidas, PhD and Lidia Oostvogels, MD; Uppsala University Hospital, Uppsala, Sweden, GSK, Wavre, Belgium, Central Laboratory and Vaccination Center, Stiftung Juliusspital, Wuerzburg, Germany, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic, Practice Dr. Toursarkissian, Berlin, Germany, Karolinska University Hospital, Stockholm, Sweden, GSK, Rixensart, Belgium
منابع مشابه
Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial
1343. Persistence of Immune Response to an Adjuvanted Varicella‐Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults Karlis Pauksens, MD; Stephanie Volpe, MPH; Tino F. Schwarz, MD; Jan Smetana, MD PhD; Nicole Toursarkissian, MD; Lars Rombo, MD; Stéphanie Ravault, PhD; Marie-Pierre David, MSc; Adriana Bastidas, PhD and Lidia Oostvogels, MD; Uppsala University Hospital, Uppsala...
متن کاملA phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.
BACKGROUND An adjuvanted recombinant varicella zoster virus (VZV) subunit vaccine is being developed for the prevention of herpes zoster and its complications. METHODS In a phase I/II, open-label, randomized, parallel-group study, older adults (50-70 years) received 2 doses 2 months apart of an adjuvanted recombinant glycoprotein E vaccine (HZ/su; n = 45), a live attenuated Oka strain VZV vac...
متن کاملA Replication-Defective Herpes Simplex Virus (HSV)-2 Vaccine, HSV529, is Safe and Well-Tolerated in Adults with or without HSV Infection and Induces Significant HSV-2-Specific Antibody Responses in HSV Seronegative Individuals
1343. Persistence of Immune Response to an Adjuvanted Varicella‐Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults Karlis Pauksens, MD; Stephanie Volpe, MPH; Tino F. Schwarz, MD; Jan Smetana, MD PhD; Nicole Toursarkissian, MD; Lars Rombo, MD; Stéphanie Ravault, PhD; Marie-Pierre David, MSc; Adriana Bastidas, PhD and Lidia Oostvogels, MD; Uppsala University Hospital, Uppsala...
متن کاملImmunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older
Background The immunogenicity and safety of an adjuvanted herpes zoster subunit (HZ/su) vaccine when coadministered with a quadrivalent seasonal inactivated influenza vaccine (IIV4) was investigated in a phase 3, open-label, randomized clinical trial in adults aged ≥50 years. Methods Subjects were randomized 1:1 to receive either HZ/su (varicella zoster virus glycoprotein E; AS01B Adjuvant Sy...
متن کاملSafety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su)
An adjuvanted recombinant subunit candidate vaccine (HZ/su) containing varicella zoster virus envelope glycoprotein E was developed for the prevention of herpes zoster and its complications. This study evaluated safety and reactogenicity of HZ/su in an ethnic Japanese population. This was a phase I, open-label and single-center study conducted between March and November of 2010 in Australia. Tw...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 4 شماره
صفحات -
تاریخ انتشار 2017